Physician profile
Robert A Atkins
NPI 1023049400
$5,916.47
in general payments reported to CMS, 2019-2025
36 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,188 · 2020: $1,113 · 2021: $987 · 2022: $156 · 2024: $112 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,191.37 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,119.80 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $325.80 | 2019-2021 | |
| Amarin Pharma, INC. | $250.28 | 2019 | |
| Janssen Biotech, INC. | $241.86 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $237.76 | 2019-2020 | |
| Ucb, INC. | $231.35 | 2019-2020 | |
| Pfizer INC. | $217.28 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $206.19 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $205.53 | 2021-2024 | Fasenra |
| Merck Sharp & Dohme LLC | $204.46 | 2019-2020 | |
| Qol Medical, LLC | $130.98 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $124.98 | 2025 | Zenpep |
| Paratek Pharmaceuticals, INC. | $122.90 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $119.78 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $110.90 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.55 | 2019 | |
| Shionogi INC | $95.37 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.89 | 2021 | |
| Amgen INC. | $78.48 | 2025 | |
| Ironwood Pharmaceuticals, INC | $77.75 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $60.70 | 2019-2020 | |
| Daiichi Sankyo INC. | $58.01 | 2019 | |
| Boston Scientific Corporation | $46.65 | 2024-2025 | Farapulse, Watchman Flx |
| Romark Laboratories, Lc | $46.61 | 2019 | |
| Allergan, INC. | $29.24 | 2019 | |
| Medtronic, INC. | $28.26 | 2021 | |
| Portola Pharmaceuticals, LLC | $26.04 | 2020 | |
| Gilead Sciences, INC. | $24.69 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $23.88 | 2022 | |
| Intra-Sana Laboratories | $20.61 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Ferring Pharmaceuticals INC. | $16.08 | 2019 | |
| Redhill Biopharma INC. | $15.88 | 2020 | |
| Vivus LLC | $14.51 | 2019 | |
| Shire North American Group INC | $14.04 | 2019 | |
| Lilly USA, LLC | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Atkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.